HLS Therapeutics Inc (HLS.TO) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Canada · ISIN CA40390B1094
HLS Therapeutics Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 56.62 m USD | 56.47 m USD |
| Gross profit | 47.62 m USD | 24.01 m USD |
| Operating income | -7.69 m USD | -4.18 m USD |
| EBIT | -5.50 m USD | -4.18 m USD |
| Net income | -19.66 m USD | -12.65 m USD |
| Diluted EPS – continuing operations | -0.62 USD | -0.40 USD |
Full history since 1996, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
More stocks
- First Resource Bank (FRSB)
- SK Securities ACPC No.7 Special Purpose Acquisition Co. Ltd. (408920.KQ)
- JELD-WEN Holding, Inc. (JELD)
- Kuen Ling Refrigerating Machinery Co Ltd (4527.TWO)
- Cibus, Inc. (CBUS)
- Tamawood Ltd (TWD.AX)
- InsCorp Inc (IBTN)
- Genic Co. Ltd (123330.KQ)
- Lee Ku Ind (025820.KS)
- Empress Royalty Corp (EMPR.V)
- Smith Douglas Homes Corp. (SDHC)
- Dual Co Ltd (016740.KS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.